EXAS - Exact Sciences Corp Stock Price, Fair Value and News

52.74USD-1.41 (-2.60%)Delayed as of 10 May 2024, 11:55 am ET

Market Summary

USD52.74-1.41

Delayedas of 10 May 2024, 11:55 am

-2.60%

EXAS Alerts

1 major insider sales recently.

Big fall in earnings (Y/Y)
Losses in recent quarter

EXAS Stock Price

View Fullscreen

EXAS RSI Chart

EXAS Valuation

Market Cap

10.0B

Price/Earnings (Trailing)

-41.57

Price/Sales (Trailing)

3.94

EV/EBITDA

-41.84

Price/Free Cashflow

-488.21

EXAS Price/Sales (Trailing)

EXAS Profitability

Operating Margin

73.67%

EBT Margin

-9.38%

Return on Equity

-7.67%

Return on Assets

-3.77%

Free Cashflow Yield

-0.2%

EXAS Fundamentals

EXAS Revenue

Revenue (TTM)

2.5B

Rev. Growth (Yr)

5.82%

Rev. Growth (Qtr)

-1.45%

EXAS Earnings

Earnings (TTM)

-240.2M

Earnings Growth (Yr)

-48.65%

Earnings Growth (Qtr)

-121.49%

Breaking Down EXAS Revenue

52 Week Range

52.51100.77

(Low)(High)

Last 7 days

-10.6%

Last 30 days

-27.1%

Last 90 days

-10.7%

Trailing 12 Months

-31.3%

How does EXAS drawdown profile look like?

EXAS Financial Health

Current Ratio

1.64

Debt/Equity

0.5

Debt/Cashflow

0.07

EXAS Investor Care

Shares Dilution (1Y)

2.30%

Diluted EPS (TTM)

-1.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.5B	0	0	0
2023	2.2B	2.3B	2.4B	2.5B
2022	1.9B	1.9B	2.0B	2.1B
2021	1.5B	1.7B	1.8B	1.8B
2020	1.1B	1.1B	1.3B	1.5B
2019	526.2M	623.2M	723.7M	876.3M
2018	307.9M	353.2M	398.9M	454.5M
2017	132.9M	169.4M	213.8M	266.0M
2016	50.0M	63.1M	78.6M	99.4M
2015	5.8M	13.9M	26.5M	39.4M
2014	3.4M	2.4M	1.3M	1.8M
2013	4.1M	4.1M	4.1M	4.1M
2012	4.2M	4.2M	4.2M	4.1M
2011	5.1M	4.8M	4.5M	4.2M
2010	0	5.0M	5.1M	5.3M
2009	0	0	0	4.8M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Exact Sciences Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 01, 2024	coward d scott	sold	-4,030	60.15	-67.00	-
May 01, 2024	orville jacob a	sold	-6,135	60.15	-102	general manager, screening
May 01, 2024	herriott james	sold	-1,804	60.15	-30.00	svp, general counsel & sec
May 01, 2024	condella sarah	sold	-6,135	60.15	-102	evp, human resources
May 01, 2024	conroy kevin t	sold	-69,473	60.15	-1,155	president and ceo
May 01, 2024	elliott jeffrey thomas	sold	-8,180	60.15	-136	chief financial officer
May 01, 2024	cunningham everett	sold	-8,180	60.15	-136	chief commercial officer
May 01, 2024	baranick brian	sold	-6,616	60.15	-110	evp, gm., precision oncology
Apr 30, 2024	orville jacob a	acquired	-	-	218	general manager, screening
Apr 30, 2024	elliott jeffrey thomas	acquired	21,224	21.2667	998	chief financial officer

Which funds bought or sold EXAS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 08, 2024	GREAT LAKES ADVISORS, LLC	reduced	-1.9	-1,382,080	15,028,900	0.13%
May 08, 2024	Belpointe Asset Management LLC	added	92.11	1,260,010	2,848,380	0.21%
May 08, 2024	US BANCORP \DE\	reduced	-15.04	-3,126,860	11,982,700	0.02%
May 08, 2024	Sandy Spring Bank	reduced	-25.47	-51,702	118,231	-%
May 08, 2024	STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM	reduced	-3.02	-1,604,330	12,832,600	0.03%
May 08, 2024	BNP PARIBAS ASSET MANAGEMENT Holding S.A.	unchanged	-	-55,000	2,223,000	0.01%
May 08, 2024	Russell Investments Group, Ltd.	added	12.52	668,352	15,257,200	0.02%
May 08, 2024	EDMOND DE ROTHSCHILD HOLDING S.A.	added	10.78	462,053	13,983,800	0.23%
May 08, 2024	Achmea Investment Management B.V.	unchanged	-	-52,000	737,000	0.01%
May 08, 2024	Bell Investment Advisors, Inc	reduced	-12.12	-877	4,006	-%

Are Funds Buying or Selling EXAS?

Are funds buying EXAS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own EXAS

No. of Funds

Unveiling Exact Sciences Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	9.71%	17,559,751	SC 13G/A
Feb 09, 2024	wellington management group llp	5.83%	10,536,759	SC 13G/A
Jan 29, 2024	blackrock inc.	6.1%	11,103,191	SC 13G/A
Jan 23, 2024	jpmorgan chase & co	9.5%	17,342,002	SC 13G/A
Oct 10, 2023	jpmorgan chase & co	10.3%	18,652,296	SC 13G
Feb 10, 2023	ark investment management llc	9.03%	16,040,490	SC 13G/A
Feb 09, 2023	vanguard group inc	9.71%	17,252,465	SC 13G/A
Feb 07, 2023	blackrock inc.	6.4%	11,354,134	SC 13G/A
Feb 06, 2023	wellington management group llp	5.86%	10,404,476	SC 13G/A
Sep 12, 2022	price t rowe associates inc /md/	3.7%	6,464,337	SC 13G/A

Recent SEC filings of Exact Sciences Corp

View All Filings

Date Filed	Form Type	Document
May 08, 2024	8-K	Current Report
May 08, 2024	8-K	Current Report
May 08, 2024	424B7	Prospectus Filed
May 08, 2024	10-Q	Quarterly Report
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading

Peers (Alternatives to Exact Sciences Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	186.3B	23.7B	0.67%	7.73%	42.31	7.85	-8.94%	-35.91%
A	42.5B	6.7B	-1.54%	13.33%	34.41	6.31	-2.81%	-6.58%
IDXX	41.4B	3.7B	-3.64%	3.26%	47.74	11.11	8.57%	23.94%
DGX	15.3B	9.3B	4.06%	4.31%	18.14	1.65	-3.29%	6.68%
MEDP	12.4B	2.0B	-1.35%	90.01%	39.59	6.3	25.57%	21.62%
CRL	11.9B	4.1B	-10.52%	23.52%	27.01	2.88	0.49%	-11.59%
NTRA	11.5B	1.1B	-1.92%	86.70%	-26.55	10.67	31.99%	20.63%
EXAS	10.0B	2.5B	-27.12%	-31.26%	-41.57	3.94	15.21%	53.51%
MID-CAP
NEOG	2.7B	929.2M	-4.60%	-27.46%	1.7K	2.9	28.93%	111.61%
GH	2.4B	603.7M	1.41%	-29.38%	-5.17	3.95	25.21%	30.68%
SMALL-CAP
CDNA	576.0M	275.1M	11.46%	29.10%	-3.14	2.09	-13.93%	-126.97%
ACRS	87.7M	31.1M	2.52%	-85.28%	-1.13	2.82	0.95%	19.75%
APDN	63.5M	9.0M	858.97%	243.12%	-8.79	7.06	-53.31%	2.21%
AWH	37.9M	9.2M	-	-31.11%	-2.27	4.14	11.85%	44.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Exact Sciences Corp News

Latest updates

Exact Sciences Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-1.4%	637,524,000	646,885,000	628,338,000	622,093,000	602,450,000	552,995,000	523,073,000	521,640,000	486,571,000	473,812,000	456,379,000	434,819,000	402,077,000	466,339,000	408,363,000	268,868,000	347,821,000	295,575,000	218,805,000	199,870,000	162,043,000
Cost Of Revenue	-1.0%	170,101,000	171,865,000	168,526,000	156,991,000	156,866,000	147,152,000	147,937,000	144,600,000	134,705,000	119,058,000	115,738,000	113,968,000	109,993,000	99,765,000	95,061,000	77,892,000	81,606,000	70,416,000	52,335,000	51,139,000	42,827,000
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	166,046,000	148,307,000	118,791,000
Costs and Expenses	3.2%	743,948,000	721,126,000	693,516,000	699,022,000	679,541,000	671,877,000	647,887,000	681,224,000	663,558,000	695,262,000	618,402,000	606,483,000	702,618,000	881,318,000	611,698,000	359,542,000	430,194,000	391,655,000	254,531,000	233,772,000	230,117,000
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	201,706,000	182,127,000	186,985,000
S&GA Expenses	1.0%	192,365,000	190,477,000	173,159,000	176,490,000	186,964,000	210,211,000	187,697,000	215,922,000	232,181,000	284,304,000	196,617,000	194,827,000	186,141,000	166,827,000	136,481,000	118,862,000	167,749,000	119,851,000	86,196,000	88,190,000	90,939,000
R&D Expenses	-3.8%	110,608,000	114,922,000	111,446,000	104,095,000	95,419,000	94,274,000	90,813,000	106,083,000	102,248,000	88,488,000	75,356,000	106,235,000	115,567,000	446,447,000	31,471,000	32,673,000	43,509,000	43,223,000	34,714,000	29,972,000	31,785,000
EBITDA Margin	-62.8%	-0.05	-0.03	-0.06	-0.13	-0.18	-0.25	-0.31	-0.33	-0.35	-0.42	-0.47	-0.51	-	-	-	-	-	-	-	-	-
Interest Expenses	-125.6%	-7,943,000	31,029,000	-7,871,000	-7,818,000	4,107,000	33,858,000	-5,235,000	-4,511,000	-4,478,000	32,554,000	-4,680,000	-4,652,000	-4,616,000	131,323,000	-4,478,000	-4,300,000	-54,604,000	-13,688,000	-13,209,000	-12,712,000	-21,990,000
Income Taxes	399.8%	1,800,000	-600,500	200,000	1,107,000	1,700,000	-2,189,500	-3,116,000	-1,751,000	-2,000,000	-4,243,000	-3,900,000	4,000,000	-242,800,000	-164,000	-2,752,000	-305,000	-2,237,000	-184,628,000	683,000	-443,000	-470,000
Earnings Before Taxes	-115.2%	-108,422,000	-50,376,000	1,043,000	-79,919,000	-72,494,000	-129,927,000	-151,877,000	-167,814,000	-182,952,000	-224,854,000	-170,796,000	-172,887,000	-273,969,000	-418,496,000	-205,290,000	-68,397,000	-136,880,000	-106,683,000	-39,842,000	-38,945,000	-83,409,000
EBT Margin	-16.2%	-0.09	-0.08	-0.12	-0.19	-0.24	-0.30	-0.36	-0.39	-0.41	-0.48	-0.59	-0.63	-	-	-	-	-	-	-	-	-
Net Income	-121.5%	-110,228,000	-49,766,000	794,000	-81,026,000	-74,151,000	-127,745,000	-148,761,000	-166,063,000	-180,937,000	-220,611,000	-166,938,000	-176,912,000	-31,164,000	-418,332,000	-202,538,000	-68,092,000	-134,643,000	77,973,000	-40,525,000	-38,502,000	-82,939,000
Net Income Margin	-16.0%	-0.09	-0.08	-0.12	-0.19	-0.23	-0.30	-0.36	-0.38	-0.40	-0.34	-0.45	-0.48	-	-	-	-	-	-	-	-	-
Free Cashflow	-446.4%	-119,960,000	34,627,000	-826,000	65,703,000	-67,575,000	-20,839,000	-85,563,000	-124,242,000	-207,377,000	-83,964,000	-79,644,000	15,753,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.5%	6,376	6,471	6,421	6,356	6,304	6,227	6,307	6,437	6,491	6,685	6,654	6,724	6,735	4,925	4,354	4,468	4,461	3,506	1,759	1,782	1,771
Current Assets	-6.2%	1,120	1,194	1,148	1,174	1,091	982	1,049	1,102	1,215	1,426	1,616	1,669	1,775	2,199	1,607	1,505	1,484	554	1,320	1,375	1,407
Cash Equivalents	-41.9%	352	605	595	604	421	242	235	213	190	315	274	364	1,104	1,492	807	704	701	178	1,034	205	285
Inventory	0.8%	129	127	133	131	124	118	115	115	113	105	95.00	90.00	89.00	92.00	80.00	82.00	69.00	62.00	54.00	48.00	44.00
Net PPE	0.5%	702	698	-	-	-	685	-	-	623	580	524	502	483	452	456	463	465	455	371	335	292
Goodwill	0.0%	2,367	2,367	2,367	2,346	2,346	2,346	2,345	2,346	2,335	2,335	2,243	2,243	57.00	1,238	1,238	1,238	30.00	1,203	-	-	-
Liabilities	-2.5%	3,244	3,326	3,300	3,299	3,247	3,184	3,198	3,228	3,232	3,297	3,197	3,165	3,086	2,690	2,017	1,957	1,923	1,218	1,011	1,016	994
Current Liabilities	33.1%	685	515	477	488	367	413	424	443	481	517	710	676	629	633	253	222	244	236	481	492	168
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,555	1,534	1,514	804	477	470	25.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.00	316	312	0.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,555	1,534	1,514	804	477	470	25.00
Shareholder's Equity	-0.4%	3,133	3,145	3,121	3,057	3,058	3,043	3,109	3,209	3,258	3,388	3,458	3,559	3,649	2,236	1,731	1,887	1,896	1,958	748	766	777
Retained Earnings	-3.2%	-3,579	-3,469	-3,419	-3,420	-3,339	-3,265	-3,137	-2,988	-2,822	-2,641	-2,420	-2,253	-2,077	-2,045	-1,531	-1,311	-1,225	-1,119	-1,197	-1,157	-1,118
Additional Paid-In Capital	1.5%	6,711	6,611	6,540	6,476	6,397	6,312	6,255	6,205	6,086	6,029	5,877	5,811	5,724	4,279	3,866	3,820	3,763	3,406	1,945	1,920	1,894
Accumulated Depreciation	6.9%	446	417	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	1.4%	184	181	181	181	180	178	176	176	174	171	172	170	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	16,796	-	-	-	6,905	-	-	-	21,212	-	-	-	12,901	-	-	-	15,070	-

Cashflow (Last 12 Months)

(In Millions)

Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-218.3%	-82.31	70.00	24.00	100	-38.22	52.00	-40.93	-60.92	-173	-24.57	-40.77	40.00	-77.23	111	82.00	-6.87	-49.83	-25.30	-29.15	17.00	-74.15
Share Based Compensation	3.1%	60.00	59.00	62.00	62.00	49.00	46.00	50.00	59.00	52.00	113	5.00	1.00	77.00	42.00	41.00	40.00	30.00	48.00	24.00	20.00	16.00
Cashflow From Investing	-156.8%	-171	-66.77	-32.97	66.00	83.00	-58.16	65.00	22.00	46.00	78.00	-49.24	-793	-317	-306	17.00	-6.38	-405	-838	857	-102	-41.20
Cashflow From Financing	-129.9%	-3.00	10.00	0.00	16.00	134	10.00	0.00	63.00	3.00	-12.20	0.00	13.00	7.00	880	4.00	16.00	979	7.00	1.00	5.00	240

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

EXAS Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 637,524	$ 602,450
Operating expenses
Cost of sales (exclusive of amortization of acquired intangible assets)	170,101	156,866
Research and development	110,608	95,419
Sales and marketing	192,365	186,964
General and administrative	243,117	217,295
Amortization of acquired intangible assets	23,311	22,928
Impairment of long-lived assets	4,446	69
Total operating expenses	743,948	679,541
Other operating loss	(268)	0
Loss from operations	(106,692)	(77,091)
Other income (expense)
Investment income, net	6,213	490
Interest income (expense), net	(7,943)	4,107
Total other income (expense)	(1,730)	4,597
Net loss before tax	(108,422)	(72,494)
Income tax expense	(1,806)	(1,657)
Net loss	$ (110,228)	$ (74,151)
Net loss per share—basic (in usd per share)	$ (0.60)	$ (0.42)
Weighted average common shares outstanding—basic (in shares)	182,350	178,574

EXAS Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 347,487	$ 605,378
Marketable securities	304,606	172,266
Accounts receivable, net	240,584	203,623
Inventory	128,534	127,475
Prepaid expenses and other current assets	99,059	85,627
Total current assets	1,120,270	1,194,369
Long-term Assets:
Property, plant and equipment, net	702,041	698,354
Operating lease right-of-use assets	142,017	143,708
Goodwill	2,367,052	2,367,120
Intangible assets, net	1,866,856	1,890,396
Other long-term assets, net	178,085	177,387
Total assets	6,376,321	6,471,334
Current liabilities:
Accounts payable	60,498	78,816
Accrued liabilities	265,121	341,683
Operating lease liabilities, current portion	27,225	29,379
Convertible Notes Payable, Current	248,810	0
Loans Payable, Current	50,000	50,000
Other current liabilities	33,455	14,823
Total current liabilities	685,109	514,701
Long-term liabilities:
Convertible notes, net, less current portion	2,066,805	2,314,276
Other long-term liabilities	329,384	335,982
Operating lease liabilities, less current portion	162,405	161,070
Total liabilities	3,243,703	3,326,029
Commitments and contingencies (Note 14)
Stockholders’ equity:
Preferred stock, $0.01 par value Authorized—5,000,000; shares issued and outstanding—no shares at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.01 par value Authorized—400,000,000; shares issued and outstanding—183,845,188 and 181,364,180 shares at March 31, 2024 and December 31, 2023	1,839	1,815
Additional paid-in capital	6,710,681	6,611,237
Accumulated other comprehensive income (loss)	(499)	1,428
Accumulated deficit	(3,579,403)	(3,469,175)
Total stockholders’ equity	3,132,618	3,145,305
Total liabilities and stockholders’ equity	$ 6,376,321	$ 6,471,334

About Exact Sciences Corp

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

CEO	Mr. Kevin T. Conroy
WEBSITE	exactsciences.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	6300

Exact Sciences Corp Frequently Asked Questions

What is the ticker symbol for Exact Sciences Corp? What does EXAS stand for in stocks?

EXAS is the stock ticker symbol of Exact Sciences Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Exact Sciences Corp (EXAS)?

As of Thu May 09 2024, market cap of Exact Sciences Corp is 9.99 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EXAS stock?

You can check EXAS's fair value in chart for subscribers.

What is the fair value of EXAS stock?

You can check EXAS's fair value in chart for subscribers. The fair value of Exact Sciences Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Exact Sciences Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for EXAS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Exact Sciences Corp a good stock to buy?

The fair value guage provides a quick view whether EXAS is over valued or under valued. Whether Exact Sciences Corp is cheap or expensive depends on the assumptions which impact Exact Sciences Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EXAS.

What is Exact Sciences Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, EXAS's PE ratio (Price to Earnings) is -41.57 and Price to Sales (PS) ratio is 3.94. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EXAS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Exact Sciences Corp's stock?

In the past 10 years, Exact Sciences Corp has provided 0.157 (multiply by 100 for percentage) rate of return.